2 blue chip healthcare shares you should own

Every investor should consider these 2 healthcare giants.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The economy is made up of a number of different sectors and businesses. The healthcare industry is one of the best sectors to invest your money in my opinion.

Here are a few reasons why you should consider Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL).

Defensive earnings

Healthcare offers shareholders a defensive earnings profile because of how integral the product or service is.

People will value being alive and healthy over most other things in life.

CSL offers a variety of services like plasma products, vaccines and pharmaceuticals which users will all value over a trip to the movies and other lifestyle expenses.

Cochlear gives its users a life changing ability to improve their hearing with hearing implants.

Ageing demographics

There is a unique set of circumstances happening now and over the next few decades where the population of people older than 65 is going to significantly increase. This should be a big boost to all the companies that benefit from elderly customers. Cochlear and CSL could be two of the biggest winners.

International expansion

Australia has a small population and it doesn't offer much room for growth. If a business can successfully expand overseas then the world becomes their oyster.

CSL and Cochlear both earn a large majority of their earnings from overseas and I imagine this will continue to be the case as they grow in Europe and North America.

Time to buy?

Cochlear is trading at 38x FY18's estimated earnings and CSL is trading at 30x FY18's estimated earnings.

Both shares are wonderful businesses but I don't think they're buys at the current prices. I'd wait until they're both at least 15% to 20% cheaper before buying over the next six months.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

This rising ASX 200 stock isn't done yet – or is it?

Inching closer to FDA approval, the share price is falling. Analysts still see 21% to 106% upside.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »

Two boys lie in the grass arm wrestling.
Healthcare Shares

Is CSL or Sonic Healthcare the smarter ASX healthcare share buy?

This ASX heavyweight has potential to deliver superior returns but is more volatile.

Read more »